



SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-29	118	PDF
Single User	Multi User	Enterprise	
USD 2,950	USD 4,430	USD 5,900	

Description

The global SGLT-2 Inhibitors for Type 2 Diabetes Treatment market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment is projected to increase from US\$ million in 2026 to US\$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

The Asia Pacific market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment include Astellas, Boehringer Ingelheim, Chugai Pharmaceutical, Taisho Pharmaceutical, AstraZeneca, Jiangsu Hengrui Medicine, Merck, Johnson & Johnson and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global SGLT-2 Inhibitors for Type 2 Diabetes Treatment market in terms of revenue (US\$ million) and, where applicable, sales volume (M Pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US\$/M Pcs) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market by Company

Astellas

Boehringer Ingelheim

Chugai Pharmaceutical
Taisho Pharmaceutical
AstraZeneca
Jiangsu Hengrui Medicine
Merck
Johnson & Johnson
Sanofi

SGLT-2 Inhibitors for Type 2 Diabetes Treatment Segment by Type

Canagliflozin
Empagliflozin
Dapagliflozin
Others

SGLT-2 Inhibitors for Type 2 Diabetes Treatment Segment by Application

E-commerce and Internet Medical Care
Offline Retail Pharmacy
Hospitals and Clinics

SGLT-2 Inhibitors for Type 2 Diabetes Treatment Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks

on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global SGLT-2 Inhibitors for Type 2 Diabetes Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of SGLT-2 Inhibitors for Type 2 Diabetes Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of SGLT-2 Inhibitors for Type 2 Diabetes Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Detailed analysis of SGLT-2 Inhibitors for Type 2 Diabetes Treatment manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5:

Production/output, value of SGLT-2 Inhibitors for Type 2 Diabetes Treatment by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6:

Consumption of SGLT-2 Inhibitors for Type 2 Diabetes Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7:

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8:

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9:

Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10:

Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
 - 2.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size (2021-2032)
 - 2.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (2021-2032)
 - 2.2.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Average Price (2021-2032)
- 2.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Type
 - 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
 - 2.3.2 Canagliflozin
 - 2.3.3 Empagliflozin
 - 2.3.4 Dapagliflozin
 - 2.3.5 Others
- 2.4 SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Application
 - 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.4.2 E-commerce and Internet Medical Care
 - 2.4.3 Offline Retail Pharmacy
 - 2.4.4 Hospitals and Clinics

3 Market Competitive Landscape by Manufacturers

- 3.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs) of Manufacturers (2021-2026)
- 3.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue of Manufacturers (2021-2026)
- 3.4 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Average Price by Manufacturers (2021-2026)
- 3.5 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Product Type & Application
- 3.8 Global Manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Established Date
- 3.9 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

4 Manufacturers Profiled

- 4.1 Astellas
 - 4.1.1 Astellas Company Information
 - 4.1.2 Astellas Business Overview
 - 4.1.3 Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
 - 4.1.4 Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio

- 4.1.5 Astellas Recent Developments
- 4.2 Boehringer Ingelheim
 - 4.2.1 Boehringer Ingelheim Company Information
 - 4.2.2 Boehringer Ingelheim Business Overview
 - 4.2.3 Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
 - 4.2.4 Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
 - 4.2.5 Boehringer Ingelheim Recent Developments
- 4.3 Chugai Pharmaceutical
 - 4.3.1 Chugai Pharmaceutical Company Information
 - 4.3.2 Chugai Pharmaceutical Business Overview
 - 4.3.3 Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
 - 4.3.4 Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
 - 4.3.5 Chugai Pharmaceutical Recent Developments
- 4.4 Taisho Pharmaceutical
 - 4.4.1 Taisho Pharmaceutical Company Information
 - 4.4.2 Taisho Pharmaceutical Business Overview
 - 4.4.3 Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
 - 4.4.4 Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
 - 4.4.5 Taisho Pharmaceutical Recent Developments
- 4.5 AstraZeneca
 - 4.5.1 AstraZeneca Company Information
 - 4.5.2 AstraZeneca Business Overview
 - 4.5.3 AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
 - 4.5.4 AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
 - 4.5.5 AstraZeneca Recent Developments
- 4.6 Jiangsu Hengrui Medicine
 - 4.6.1 Jiangsu Hengrui Medicine Company Information
 - 4.6.2 Jiangsu Hengrui Medicine Business Overview
 - 4.6.3 Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
 - 4.6.4 Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
 - 4.6.5 Jiangsu Hengrui Medicine Recent Developments
- 4.7 Merck
 - 4.7.1 Merck Company Information
 - 4.7.2 Merck Business Overview
 - 4.7.3 Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
 - 4.7.4 Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
 - 4.7.5 Merck Recent Developments
- 4.8 Johnson & Johnson
 - 4.8.1 Johnson & Johnson Company Information
 - 4.8.2 Johnson & Johnson Business Overview
 - 4.8.3 Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
 - 4.8.4 Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
 - 4.8.5 Johnson & Johnson Recent Developments
- 4.9 Sanofi
 - 4.9.1 Sanofi Company Information

4.9.2 Sanofi Business Overview

4.9.3 Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)

4.9.4 Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio

4.9.5 Sanofi Recent Developments

5 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Scenario by Region

5.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Region: 2021 VS 2025 VS 2032

5.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2021-2032

5.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2021-2026

5.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2027-2032

5.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2021-2032

5.3.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2021-2026

5.3.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2027-2032

5.4 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country

5.4.1 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2021 VS 2025 VS 2032

5.4.2 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2032)

5.4.3 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2021-2032)

5.4.4 United States

5.4.5 Canada

5.5 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country

5.5.1 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2021 VS 2025 VS 2032

5.5.2 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2032)

5.5.3 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2021-2032)

5.5.4 Germany

5.5.5 France

5.5.6 U.K.

5.5.7 Italy

5.5.8 Netherlands

5.6 Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country

5.6.1 Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2021 VS 2025 VS 2032

5.6.2 Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2032)

5.6.3 Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2021-2032)

5.6.4 China

5.6.5 Japan

5.6.6 South Korea

5.6.7 India

5.6.8 Australia

5.6.9 China Taiwan

5.6.10 Southeast Asia

5.7 South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country

5.7.1 South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2021 VS 2025 VS 2032

5.7.2 South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2032)

5.7.3 South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2021-2032)

5.7.4 Mexico

5.7.5 Brazil

5.7.6 Argentina

5.7.7 Colombia

5.8 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country

5.8.1 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2021 VS 2025 VS 2032

5.8.2 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2032)

5.8.3 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2021-2032)

5.8.4 Turkey

5.8.5 Saudi Arabia

5.8.6 UAE

6 Segment by Type

6.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2032)

6.1.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2032) & (M Pcs)

6.1.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2021-2032)

6.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2021-2032)

6.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2032) & (US\$ Million)

6.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2021-2032)

6.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Type (2021-2032)

7 Segment by Application

7.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2032)

7.1.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2032) & (M Pcs)

7.1.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2021-2032)

7.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2021-2032)

7.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2032) & (US\$ Million)

7.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2021-2032)

7.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Application (2021-2032)

8 Value Chain and Sales Channels Analysis of the Market

8.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Value Chain Analysis

8.1.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Key Raw Materials

8.1.2 Raw Materials Key Suppliers

8.1.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Production Mode & Process

8.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Channels Analysis

8.2.1 Direct Comparison with Distribution Share

8.2.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Distributors

8.2.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Customers

9 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Analyzing Market Dynamics

9.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Trends

9.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Drivers

9.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Opportunities and Challenges

9.4 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Restraints

10 Report Conclusion

11 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
- Table 6: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs) of Manufacturers (2021-2026)
- Table 7: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Manufacturers (2021-2026)
- Table 8: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue of Manufacturers (2021-2026)
- Table 9: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Manufacturers (2021-2026)
- Table 10: Global Market SGLT-2 Inhibitors for Type 2 Diabetes Treatment Average Price (US\$/K Pcs) of Manufacturers (2021-2026)
- Table 11: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Ranking, 2024 VS 2025 VS 2026
- Table 12: Global Manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Manufacturing Sites & Headquarters
- Table 13: Global Manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Product Type & Application
- Table 14: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Manufacturers Established Date
- Table 15: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 17: Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18: Astellas Company Information
- Table 19: Astellas Business Overview
- Table 20: Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US\$ Million), Price (US\$/K Pcs) and Gross Margin (2021-2026)
- Table 21: Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
- Table 22: Astellas Recent Developments
- Table 23: Boehringer Ingelheim Company Information
- Table 24: Boehringer Ingelheim Business Overview
- Table 25: Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US\$ Million), Price (US\$/K Pcs) and Gross Margin (2021-2026)
- Table 26: Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
- Table 27: Boehringer Ingelheim Recent Developments
- Table 28: Chugai Pharmaceutical Company Information
- Table 29: Chugai Pharmaceutical Business Overview
- Table 30: Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US\$ Million), Price (US\$/K Pcs) and Gross Margin (2021-2026)
- Table 31: Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
- Table 32: Chugai Pharmaceutical Recent Developments
- Table 33: Taisho Pharmaceutical Company Information
- Table 34: Taisho Pharmaceutical Business Overview
- Table 35: Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US\$ Million), Price (US\$/K Pcs) and Gross Margin (2021-2026)
- Table 36: Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
- Table 37: Taisho Pharmaceutical Recent Developments
- Table 38: AstraZeneca Company Information
- Table 39: AstraZeneca Business Overview
- Table 40: AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US\$ Million), Price (US\$/K Pcs) and Gross Margin (2021-2026)
- Table 41: AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
- Table 42: AstraZeneca Recent Developments
- Table 43: Jiangsu Hengrui Medicine Company Information
- Table 44: Jiangsu Hengrui Medicine Business Overview
- Table 45: Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US\$ Million), Price (US\$/K Pcs) and Gross Margin (2021-2026)
- Table 46: Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio

- Table 47: Jiangsu Hengrui Medicine Recent Developments
- Table 48: Merck Company Information
- Table 49: Merck Business Overview
- Table 50: Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US\$ Million), Price (US\$/K Pcs) and Gross Margin (2021-2026)
- Table 51: Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
- Table 52: Merck Recent Developments
- Table 53: Johnson & Johnson Company Information
- Table 54: Johnson & Johnson Business Overview
- Table 55: Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US\$ Million), Price (US\$/K Pcs) and Gross Margin (2021-2026)
- Table 56: Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
- Table 57: Johnson & Johnson Recent Developments
- Table 58: Sanofi Company Information
- Table 59: Sanofi Business Overview
- Table 60: Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US\$ Million), Price (US\$/K Pcs) and Gross Margin (2021-2026)
- Table 61: Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
- Table 62: Sanofi Recent Developments
- Table 63: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 64: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2021-2026) & (M Pcs)
- Table 65: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2021-2026)
- Table 66: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2027-2032) & (M Pcs)
- Table 67: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2027-2032)
- Table 68: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2021-2026) & (US\$ Million)
- Table 69: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region (2021-2026)
- Table 70: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2027-2032) & (US\$ Million)
- Table 71: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region (2027-2032)
- Table 72: North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 73: North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs)
- Table 74: North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2027-2032) & (M Pcs)
- Table 75: North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2021-2026) & (US\$ Million)
- Table 76: North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2027-2032) & (US\$ Million)
- Table 77: Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 78: Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs)
- Table 79: Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2027-2032) & (M Pcs)
- Table 80: Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2021-2026) & (US\$ Million)
- Table 81: Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2027-2032) & (US\$ Million)
- Table 82: Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 83: Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs)
- Table 84: Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2027-2032) & (M Pcs)
- Table 85: Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2021-2026) & (US\$ Million)
- Table 86: Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2027-2032) & (US\$ Million)
- Table 87: South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 88: South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs)
- Table 89: South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2027-2032) & (M Pcs)
- Table 90: South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2021-2026) & (US\$ Million)
- Table 91: South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2027-2032) & (US\$ Million)
- Table 92: Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 93: Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs)
- Table 94: Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2027-2032) & (M Pcs)
- Table 95: Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2021-2026) & (US\$ Million)
- Table 96: Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2027-2032) & (US\$ Million)
- Table 97: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (M Pcs)
- Table 98: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2027-2032) & (M Pcs)
- Table 99: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2021-2026)
- Table 100: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2027-2032)
- Table 101: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2021-2026) & (US\$ Million)

- Table 102: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2027-2032) & (US\$ Million)
- Table 103: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2021-2026)
- Table 104: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2027-2032)
- Table 105: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Type (2021-2026) & (US\$/K Pcs)
- Table 106: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Type (2027-2032) & (US\$/K Pcs)
- Table 107: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (M Pcs)
- Table 108: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2027-2032) & (M Pcs)
- Table 109: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2021-2026)
- Table 110: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2027-2032)
- Table 111: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2021-2026) & (US\$ Million)
- Table 112: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2027-2032) & (US\$ Million)
- Table 113: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2021-2026)
- Table 114: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2027-2032)
- Table 115: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Application (2021-2026) & (US\$/K Pcs)
- Table 116: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Application (2027-2032) & (US\$/K Pcs)
- Table 117: Key Raw Materials
- Table 118: Raw Materials Key Suppliers
- Table 119: SGLT-2 Inhibitors for Type 2 Diabetes Treatment Distributors List
- Table 120: SGLT-2 Inhibitors for Type 2 Diabetes Treatment Customers List
- Table 121: SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Trends
- Table 122: SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Drivers
- Table 123: SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Restraints
- Table 124: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Image
- Figure 5: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (US\$ Million), 2021 VS 2025 VS 2032
- Figure 6: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size (2021-2032) & (US\$ Million)
- Figure 7: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (2021-2032) & (M Pcs)
- Figure 8: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Average Price (US\$/K Pcs) & (2021-2032)
- Figure 9: Canagliflozin Product Image
- Figure 10: Empagliflozin Product Image
- Figure 11: Dapagliflozin Product Image
- Figure 12: Others Product Image
- Figure 13: E-commerce and Internet Medical Care Product Image
- Figure 14: Offline Retail Pharmacy Product Image
- Figure 15: Hospitals and Clinics Product Image
- Figure 16: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Manufacturers in 2025
- Figure 17: Global Manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Manufacturing Sites & Headquarters
- Figure 18: Global Top 5 and 10 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Players Market Share by Revenue in 2025
- Figure 19: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 20: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Figure 21: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region in 2025
- Figure 22: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region in 2025
- Figure 23: North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country in 2025
- Figure 24: North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2021-2032)
- Figure 25: North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2021-2032)
- Figure 26: United States SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 27: Canada SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 28: Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country in 2025
- Figure 29: Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2021-2032)
- Figure 30: Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2021-2032)
- Figure 31: Germany SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 32: France SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 33: U.K. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 34: Italy SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 35: Netherlands SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 36: Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country in 2025
- Figure 37: Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2021-2032)

- Figure 38: Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2021-2032)
- Figure 39: China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 40: Japan SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 41: South Korea SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 42: India SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 43: Australia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 44: China Taiwan SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 45: Southeast Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 46: Southeast Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 47: South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country in 2025
- Figure 48: South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2021-2032)
- Figure 49: South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2021-2032)
- Figure 50: Mexico SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 51: Brazil SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 52: Argentina SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 53: Colombia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 54: Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country in 2025
- Figure 55: Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2021-2032)
- Figure 56: Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2021-2032)
- Figure 57: Turkey SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 58: Saudi Arabia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 59: UAE SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 60: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2021-2032)
- Figure 61: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2021-2032)
- Figure 62: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price (US\$/K Pcs) by Type (2021-2032)
- Figure 63: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2021-2032)
- Figure 64: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2021-2032)
- Figure 65: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price (US\$/K Pcs) by Application (2021-2032)
- Figure 66: SGLT-2 Inhibitors for Type 2 Diabetes Treatment Value Chain
- Figure 67: SGLT-2 Inhibitors for Type 2 Diabetes Treatment Production Mode & Process
- Figure 68: Direct Comparison with Distribution Share
- Figure 69: Distributors Profiles
- Figure 70: SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Opportunities and Challenges